Details of the Drug Combination

General Information of Drug Combination (ID: DCKQAM0)

Drug Combination Name
Diosmin Rivaroxaban
Indication
Disease Entry Status REF
Deep Vein Thrombosis Phase 4 [1]
Component Drugs Diosmin   DM29M30 Rivaroxaban   DMQMBZ1
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Diosmin
Disease Entry ICD 11 Status REF
Hemorrhoids DB60 Approved [2]
Indication(s) of Rivaroxaban
Disease Entry ICD 11 Status REF
Deep vein thrombosis BD71 Approved [3]
Heparin-induced thrombocytopenia 3B64.12 Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Rivaroxaban Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Rivaroxaban Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Rivaroxaban Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [9]
Cytochrome P450 2J2 (CYP2J2) DERSX5P CP2J2_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Rivaroxaban Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Hydroxylation [10]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Increases Hydroxylation [10]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03413618) Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6388).
4 Rivaroxaban FDA Label
5 Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 (COVID-PREVENT)
6 Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019 Feb 6.
7 Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70.
8 Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
9 Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40.
10 Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib. Chem Res Toxicol. 2021 Jul 19;34(7):1800-1813. doi: 10.1021/acs.chemrestox.1c00178. Epub 2021 Jun 30.